Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis

The anatomic peritoneum is often considered equivalent to the barrier between the dialysate and the blood, and is also called “the peritoneal membrane.” Our hypothesis is that the normal peritoneum is not a significant barrier to solute or water flow. The goal of this study was to explore the effects of alteration of the anatomic peritoneum on the transperitoneal transport of water and solute.

In vivo transport experiments were carried out in control and treated rats. Treatments consisted of frequent mixing of the peritoneal solution versus no mixing, drying the peritoneum prior to the experiment, or selective removal of the entire peritoneum. Transport experiments were carried out via a plastic chamber affixed to the parietal peritoneum. After measuring solute transport or osmotically induced filtration, the tissue underlying the chamber was collected and stained for histology.

Mixing the chamber solution every 5 minutes versus no mixing over 90 minutes did not result in a significant change in the mass transfer coefficient for mannitol (MTC_mannitol, n = 14, p > 0.25). Drying the peritoneum prior to the transport experiment did not significantly alter the MTC of albumin or mannitol (n = 17, p > 0.6; n = 19, p > 0.1, respectively). Manual drying did not remove or significantly alter the apparent peritoneal coating on the surface of the mesothelium. Removal of the entire peritoneum did not significantly alter the osmotically induced volume flux from the tissue, nor did it change the MTC_mannitol (n = 9, p > 0.9; n = 9, p > 0.4, respectively).

Mixing of the solution directly over the tissue, manual drying of the peritoneum, or removal of the entire peritoneum does not result in significant alterations in transport. We conclude that the anatomic peritoneum is relatively unimportant as a physical transport barrier in peritoneal dialysis.

Malnutrition is common among peritoneal dialysis (PD) patients. Reduced nutrient intake contributes to this. It has long been assumed that this reflects disturbed appetite. We set out to define the appetite profiles of a group of PD patients using a novel technique.

Prospective, cross-sectional comparison of PD patients versus controls.

Teaching hospital dialysis unit.

39 PD patients and 42 healthy controls.

Visual analog ratings were recorded at hourly intervals to generate daily profiles for hunger and fullness. Summary statistics were generated to compare the groups. Food intake was measured using 3-day dietary records.

Hunger and fullness profiles. Derived hunger and fullness scores.

Controls demonstrated peaks of hunger before mealtimes, with fullness scores peaking after meals. The PD profiles had much reduced premeal hunger peaks. A postmeal reduction in hunger was evident, but the rest of the trace was flat. The PD fullness profile was also flatter than in the controls. Mean scores were similar despite the marked discrepancy in the profiles. The PD group had lower peak hunger and less diurnal variability in their hunger scores. They also demonstrated much less change in fullness rating around mealtimes, while the mean and peak fullness scores were little different. The reported nutrient intake was significantly lower for PD.

The data suggest that PD patients normalize their mean appetite perception at a lower level of nutrient intake than controls, suggesting that patient-reported appetite may be misleading in clinical practice. There is a loss of the usual daily variation for the PD group, which may contribute to their reduced food intake. The technique described here could be used to assess the impact of interventions upon the abnormal PD appetite profile.

The aim of this study was to investigate the nutritional status of children on continuous ambulatory peritoneal dialysis (CAPD) and to relate it to the dose of dialysis and serum levels of inflammatory cytokines and insulin-like growth factor-1 (IGF-1).

17 CAPD patients (8 girls, 9 boys; mean age 13.1 ± 3.5 years, median 15 years) were included in the study. Anthropometric measurements and serum albumin levels were used in the evaluation of nutritional status. Serum interleukin (IL)-1β, IL-6, tumor necrosis factor α, and IGF-1 levels were determined in all CAPD patients and in a healthy control group. Weekly Kt/V and creatinine clearance (CCr) were measured to determine adequacy of dialysis.

The mean dialysis period was 23.7 ± 15.2 months (median 23 months). Anthropometric measurements and serum albumin level were as follows: height 130.2 ± 15.6 cm, height standard deviation score (HtSDS) -4.2 ± 2.4, body mass index (BMI) 16.3 ± 1.6 kg/m², body mass index standard deviation score (BMISDS) -0.8 ± 0.9, triceps skinfold thickness (TST) 4.2 ± 1.4 mm, midarm circumference (MAC) 16.21 ± 2.3 cm, upper arm muscle area (AMA) 1799.1 ± 535.7 mm², upper arm fat area (AFA) 334.5 ± 143 mm², and serum albumin 3.1 ± 0.7 g/dL. The BMI was above the fifth percentile in all patients; TST and MAC were below the fifth percentile in 14 patients (82.4%) and 10 patients (58.8%) respectively. The AMA was below the fifth percentile in 8 patients; however, the AFA was below the fifth percentile in all patients. Mean serum albumin level was under 3.5 g/dL in 70.5% of the children. We found significant positive correlations between BMI and Kt/V (r = 0.69, p < 0.01), CCr (r = 0.64, p < 0.05), and IL-6 (r = 0.61, p < 0.01). There was an inverse correlation between BMISDS and dialysis period (r = -0.58, p < 0.05); and between IL-6 and serum albumin (r = -0.49, p < 0.05). A significant positive correlation between BMISDS and serum IGF-1 level (r = 0.62, p < 0.01) was noted. We also found a significant positive correlation between serum IGF-1 level and both HtSDS (r = 0.57, p < 0.05) and TST (r = 0.52, p < 0.05). Significant positive correlations between AFA and CCr and IGF-1 were also noted (both r = 0.56, p < 0.05).

Although many factors may be responsible for malnutrition and growth retardation, we found that prolonged period of dialysis, inadequate dialysis, and low IGF-1 levels are the most important risk factors in CAPD patients.

It is still not clear whether hypertension and left ventricular hypertrophy (LVH) are more common in continuous ambulatory peritoneal dialysis (CAPD) than in hemodialysis (HD) patients.

To examine this subject, the indices of cardiac performance were compared between 50 HD and 34 CAPD patients. Patients were further divided into two subgroups [long-term (L) CAPD and L-HD] according to dialysis modality and duration of dialysis (more than 60 months’ duration).

The blood pressure and cardiothoracic index of CAPD patients did not differ from HD patients. On average, the left atrial index was 2 mm/m² higher in HD patients than in CAPD patients. Left ventricular chamber sizes, wall thickness, and left ventricular mass index (LVMI) in patients on CAPD were similar to those of HD patients. Isovolumic relaxation time (IVRT) of CAPD patients was insignificantly less than that of HD patients (101 ± 22 and 115 ± 27 msec respectively). There was no significant difference between the two subgroups (L-HD and L-CAPD) in blood pressure, left atrial diameter, left ventricular chamber size, wall thickness, LVMI, ejection fraction, or IVRT.

If normovolemia and normotension are obtained by strict volume control without using antihypertensive drugs, the effects of the two modalities of chronic dialysis treatment (HD and CAPD) on cardiac structure and function are not different from each other.

Comorbidity is a strong predictor and confounds many studies of outcomes. Previous studies have shown that the Charlson Comorbidity Index (CCI) and the Davies score predict mortality in peritoneal dialysis (PD) patients. However, there are few data on the comparison of comorbidity scores.

To compare the CCI (combines comorbidity and age) and Davies score (comorbidity score without age) to see if one score was superior to the other in predicting outcomes.

Prospective database study.

Seven dialysis centers in Western Pennsylvania.

415 incident PD patients, starting PD from 1/1/90 to 2/1/00.

The CCI and Davies score calculated at the start of PD; serum albumin levels and demographics at the start of PD; total hospitalizations and mortality, collected prospectively.

The correlation between CCI and Davies was 0.80, p < 0.0001. The CCI was inversely correlated with serum albumin (–0.31, p < 0.0001). Davies was significantly correlated with age (0.32, p < 0.0001) and inversely correlated with albumin (–0.27, p < 0.0001). The CCI alone was a stronger predictor than Davies alone (score by best subsets regression 49.6 vs 42.0, p = 0.0058). The CCI and Davies with age appeared to be equivalent models of survival (49.61 vs 49.64). The best predictive models were CCI and initial albumin, or Davies, age, and initial albumin. Both CCI and Davies were predictors of hospitalization rates, but the model with the Davies score was better (Akaike information criterion 799.2 vs 850.2). The best predictive model was Davies, albumin, age, and race.

Both comorbidity scores were significant predictors of outcomes, with CCI the stronger predictor for mortality, but the Davies was a stronger predictor of hospitalizations. One or both should be done at the start of dialysis to predict outcome.

The aim of this study was to measure and evaluate the appropriateness of the actual concentrations of serum and dialysate ceftazidime in Thai continuous ambulatory peritoneal dialysis (CAPD) patients.

Prospective and descriptive study of patients treated following the International Society for Peritoneal Dialysis (ISPD) 2000 recommendation for the empiric therapy of CAPD-related peritonitis.

Institutional level of clinical care.

CAPD-related peritonitis patients were diagnosed by dialysate effluent white blood cell count of more than 100/mm³ and polymorphonuclear leukocytes of at least 50%. There were 10 patients, all at least 18 years of age, entered; all completed the study.

In accordance with the ISPD 2000 recommendations, the antibiotic regimen comprised continuous intraperitoneal (IP) cefazolin and once-daily IP ceftazidime. Cefazolin was administered as loading and continuous maintenance doses of 500 and 125 mg/L dialysate respectively. Ceftazidime (20 mg/kg body weight) was given IP once daily. Duration of treatment was 96 hours.

Serum and dialysate effluent samples of the 10 CAPD patients with peritonitis were measured for ceftazidime levels, which were used for the development of pharmacokinetic equations that could predict drug concentrations at any treatment time.

Following ceftazidime administration as in the ISPD 2000 recommendation, serum ceftazidime levels were above 8 μg/mL, the minimum inhibitory concentration (MIC) recommended by NCCLS, throughout 24 hours. Dialysate ceftazidime levels were below the MIC for total periods of 4.19 and 6.26 hours in day 1 and day 4 respectively. The clinical response rate to the empiric regimen was 90%.

Once-daily IP administration of ceftazidime according to the ISPD 2000 recommendation could not provide adequately therapeutic levels of ceftazidime in dialysate throughout 24 hours. Despite this finding and the poor post-antibiotic property of ceftazidime, the empiric regimen including once-daily IP ceftazidime could yield good clinical outcome.

The use of peritoneal dialysis has expanded in many developing subtropical countries; however, the role of climatic factors in dialysis-related peritonitis has not been studied in detail.

Retrospective study.

A single regional dialysis unit in a university teaching hospital.

We reviewed all cases of dialysis-related peritonitis treated in our dialysis unit from January 1995 to December 2001. Information was collected on demographic data, microbiologic etiology, associated catheter exit-site infection, and clinical response.

In 24 059 patient-months of follow-up, 1344 episodes of peritonitis were recorded. There were significantly more peritonitis episodes in July and August [odds ratio 1.17, 95% confidence interval (CI) 1.03 – 1.32], and fewer peritonitis episodes in December (odds ratio 0.79, 95% CI 0.61 – 0.98). There was also a trend of more peritonitis in March (odds ratio 1.18, 95% CI 0.97 – 1.41), but the difference was not statistically significant. When the incidence of peritonitis caused by individual bacterial species was further analyzed, we found a significant seasonal variation in the rate of peritonitis caused by gram-negative bacteria, except Pseudomonas (overall chi-square test, p = 0.002). A similar trend of seasonal variation was also observed in gram-positive peritonitis, but the result was not statistically significant. There was significant seasonal variation in the rate of peritonitis that had coexisting exit-site infection (overall chi-square test, p = 0.02), with peak incidence in July. However, the proportion of peritonitis that had coexisting exit-site infection did not have significant seasonal variation. There was significant correlation between monthly peritonitis rate and average humidity (r = –0.346, p < 0.002) and temperature (r = –0.264, p = 0.015).

There is substantial seasonal variation in the incidence of dialysis-related peritonitis, with peak incidence in the months that are hot and humid. Keeping a cool and dry living environment may help to reduce peritonitis in peritoneal dialysis patients in tropical countries.